Croda International (CRDA) Stock Overview
Engages in the consumer care, life science, and industrial specialty businesses in Europe, the Middle East, Africa, North America, Asia, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
CRDA Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Croda International Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£27.85 |
| 52 Week High | UK£38.21 |
| 52 Week Low | UK£24.27 |
| Beta | 0.97 |
| 1 Month Change | -3.03% |
| 3 Month Change | 8.41% |
| 1 Year Change | -22.77% |
| 3 Year Change | -60.75% |
| 5 Year Change | -55.78% |
| Change since IPO | 1,638.37% |
Recent News & Updates
Croda International (LON:CRDA) Will Be Hoping To Turn Its Returns On Capital Around
Oct 06
Croda International Plc's (LON:CRDA) P/E Is On The Mark
Sep 18Recent updates
Croda International (LON:CRDA) Will Be Hoping To Turn Its Returns On Capital Around
Oct 06Croda International Plc's (LON:CRDA) P/E Is On The Mark
Sep 18Here's Why Croda International (LON:CRDA) Can Manage Its Debt Responsibly
Aug 15Croda International Plc's (LON:CRDA) Intrinsic Value Is Potentially 35% Above Its Share Price
Jul 12Here's Why Croda International (LON:CRDA) Can Manage Its Debt Responsibly
May 08What Croda International Plc's (LON:CRDA) P/E Is Not Telling You
Apr 11Is There An Opportunity With Croda International Plc's (LON:CRDA) 24% Undervaluation?
Mar 30
Acquisition Of Solus Biotech And Asian Expansion Will Strengthen Future Outlook
Strengthening local relationships and strategic acquisitions, particularly in Asia, should drive revenue through higher prices and increased manufacturing capacity.Croda International (LON:CRDA) Will Be Hoping To Turn Its Returns On Capital Around
Feb 18Croda International (LON:CRDA) Has A Somewhat Strained Balance Sheet
Dec 10Shareholder Returns
| CRDA | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | -3.6% | -3.7% | -0.1% |
| 1Y | -22.8% | -6.3% | 18.2% |
Return vs Industry: CRDA underperformed the UK Chemicals industry which returned -6.3% over the past year.
Return vs Market: CRDA underperformed the UK Market which returned 18.2% over the past year.
Price Volatility
| CRDA volatility | |
|---|---|
| CRDA Average Weekly Movement | 4.0% |
| Chemicals Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: CRDA has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: CRDA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 6,027 | Steve Foots | www.croda.com |
Croda International Plc engages in the consumer care, life science, and industrial specialty businesses in Europe, the Middle East, Africa, North America, Asia, and Latin America. The company offers consumer care products across beauty care, beauty actives, and home care products, as well as fragrances and flavours. It also provides biologics drug delivery, crop protection, and seed coating systems and enhancement technologies to improve germination.
Croda International Plc Fundamentals Summary
| CRDA fundamental statistics | |
|---|---|
| Market cap | UK£3.90b |
| Earnings (TTM) | UK£139.90m |
| Revenue (TTM) | UK£1.67b |
Is CRDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRDA income statement (TTM) | |
|---|---|
| Revenue | UK£1.67b |
| Cost of Revenue | UK£915.70m |
| Gross Profit | UK£752.30m |
| Other Expenses | UK£612.40m |
| Earnings | UK£139.90m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Feb 24, 2026
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 45.10% |
| Net Profit Margin | 8.39% |
| Debt/Equity Ratio | 29.5% |
How did CRDA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/06 18:38 |
| End of Day Share Price | 2025/11/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Croda International Plc is covered by 35 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Bate | Barclays |
| James Knight | Barclays |
| James Stewart | Barclays |